Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRK

Merck & Co Inc

Sep 12 • 04:00PM ET

82.81

-2.34 -2.75 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: PFE AZN NVS BMY JNJ AMGN ABBV GSK LLY SNY

| Held by: VTI VOO SCHD SPY IVV VTV XLV VIG VYM DGRO

Scroll to Statements

Index	DJIA, S&P 500	P/E	12.77	EPS (ttm)	6.49	Insider Own	0.10%	Shs Outstand	2.50B	Perf Week	-2.24%
Market Cap	206.84B	Forward P/E	8.59	EPS next Y	9.64	Insider Trans	-0.17%	Shs Float	2.50B	Perf Month	0.12%
Enterprise Value	233.65B	PEG	1.15	EPS next Q	2.37	Inst Own	80.16%	Short Float	0.95%	Perf Quarter	1.21%
Income	16.41B	P/S	3.26	EPS this Y	16.60%	Inst Trans	-0.99%	Short Ratio	1.73	Perf Half Y	-12.56%
Sales	63.43B	P/B	4.23	EPS next Y	8.04%	ROA	14.26%	Short Interest	23.83M	Perf YTD	-16.76%
Book/sh	19.57	P/C	23.87	EPS next 5Y	11.14%	ROE	35.44%	52W High	119.38 -30.63%	Perf Year	-28.20%
Cash/sh	3.47	P/FCF	14.05	EPS past 3/5Y	9.42% 12.04%	ROIC	19.78%	52W Low	73.31 12.96%	Perf 3Y	-4.67%
Dividend Est.	3.14 (3.79%)	EV/EBITDA	8.73	Sales past 3/5Y	9.36% 6.55%	Gross Margin	75.25%	Volatility	1.71% 1.83%	Perf 5Y	1.88%
Dividend TTM	3.20 (3.86%)	EV/Sales	3.68	EPS Y/Y TTM	20.01%	Oper. Margin	35.05%	ATR (14)	1.71	Perf 10Y	64.95%
Dividend Ex-Date	Sep 15, 2025	Quick Ratio	1.17	Sales Y/Y TTM	2.00%	Profit Margin	25.87%	RSI (14)	46.49	Recom	1.96
Dividend Gr. 3/5Y	5.73% 6.66%	Current Ratio	1.42	EPS Q/Q	-17.85%	SMA20	-2.13%	Beta	0.38	Target Price	102.19
Payout	46.32%	Debt/Eq	0.72	Sales Q/Q	-2.20%	SMA50	-0.04%	Rel Volume	0.72	Prev Close	85.15
Employees	75000	LT Debt/Eq	0.69	Earnings	Jul 29 BMO	SMA200	-5.11%	Avg Volume	13.80M	Price	82.81
IPO	Jun 15, 1946	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.77% -0.37%	Trades		Volume	9,925,413	Change	-2.75%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Citigroup	Buy → Neutral	$84
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$85
Feb-18-25	Downgrade	Deutsche Bank	Buy → Hold	$128 → $105
Feb-10-25	Downgrade	TD Cowen	Buy → Hold	$121 → $100
Jan-08-25	Downgrade	Truist	Buy → Hold	$110
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$136 → $105
Dec-10-24	Resumed	BofA Securities	Buy	$121
Dec-04-24	Upgrade	HSBC Securities	Hold → Buy	$130
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-11-24	Downgrade	Daiwa Securities	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform	$115
Mar-11-24	Downgrade	Societe Generale	Hold → Sell	$104
Jan-04-24	Upgrade	TD Cowen	Market Perform → Outperform	$125 → $135
Nov-09-23	Initiated	Deutsche Bank	Buy	$115
Oct-27-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$132
Oct-20-23	Upgrade	UBS	Neutral → Buy	$117 → $122
Jul-14-23	Initiated	HSBC Securities	Hold	$123
Apr-13-23	Upgrade	Citigroup	Neutral → Buy	$105 → $130
Mar-28-23	Downgrade	Societe Generale	Buy → Hold
Mar-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$120 → $115

Show Previous Ratings

Sep-12-25 08:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
12:38PM	Exclusive-AstraZeneca pauses $270 million investment in Britain (Reuters)
10:57AM	Merck & Co., Inc. (MRK) Reports Positive Topline Results from its Phase 3 CORALreef Lipids Trial (Insider Monkey)
10:25AM	Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects (Zacks)
09:08AM	BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? (Zacks)
06:39AM	Loading…
06:39AM	Health Care Roundup: Market Talk (The Wall Street Journal)
03:00AM	Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl (Barrons.com)
Sep-11-25 05:45PM	Merck (MRK) Outpaces Stock Market Gains: What You Should Know (Zacks)
04:58PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:28PM	MSD calls off £1bn UK expansion amid government-big pharma tensions (Pharmaceutical Technology)
10:05AM	Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock? (Zacks)
09:52AM	Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? (Zacks)
06:45AM	CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease (Business Wire)
05:42AM	Britain defends investment record as Merck scraps labs over pharma environment (Reuters)
Sep-10-25 03:11PM	US pharma giant Merck ditches plan for $1.4-bn research centre in UK (AFP)
12:14PM	Loading…
12:14PM	Merck to scrap London drug research centre (Reuters)
12:07PM	Merck managers awkward whispers didnt constitute harassment, judge rules (HR Dive)
11:02AM	J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum (Zacks)
07:33AM	Kriya, Odyssey secure megarounds; Amgen boosts R&D leadership (BioPharma Dive)
Sep-09-25 01:17PM	SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study (Zacks)
11:21AM	Will LLY's Oncology Portfolio Provide Key Diversification Benefits? (Zacks)
08:50AM	Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds? (Zacks)
Sep-08-25 04:08PM	Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch (Investor's Business Daily)
09:15AM	J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? (Zacks)
08:28AM	Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences (Benzinga)
07:53AM	New Summit data clouds approval pathway in lung cancer (BioPharma Dive)
Sep-07-25 10:45AM	Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial (Business Wire)
10:23AM	Leerink Partners Maintained a Buy on Merck & Co (MRK) (Insider Monkey)
07:00AM	Companies Kick Off September With Deluge of Bond Sales (The Wall Street Journal)
Sep-05-25 02:23PM	WHO adds weight loss drugs to essential medicines list (Quartz)
02:17PM	Loading…
02:17PM	Companies tap US bond market for nearly $70 billion, starting September on a busy note (Reuters)
11:05AM	Merck (MRK) Impresses with New Cholesterol Drug in CORALreef Trial (Insider Monkey)
Sep-04-25 09:36AM	NSCLC: three trials to keep an eye on (Clinical Trials Arena)
Sep-03-25 10:27AM	US corporate debt market returns in force after market holiday (Reuters)
10:07AM	MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline (Zacks)
10:04AM	J&J Gears Up for Some Key New Drug Approvals and Launches (Zacks)
Sep-02-25 06:00PM	More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. (Barrons.com)
01:36PM	This Merck Pill Promises Powerful Cholesterol Reduction Without Injections (Benzinga)
12:57PM	Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? (Motley Fool)
11:31AM	Analyst Report: Merck & Co., Inc. (Morningstar Research)
11:12AM	Leerink Partners Remains Bullish on Merck & Co. (MRK) (Insider Monkey)
10:10AM	Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth? (Zacks)
09:58AM	Can Korlym Drive Corcept's Growth Through the Rest of 2025? (Zacks)
06:30AM	Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
03:27AM	Merck & Co., Inc. (MRK) Launches $3B Plan to Reinvest Ahead of Keytruda Patent Expiry in 2028 (Insider Monkey)
12:45AM	Merck & Co. Inc. (MRK) Initiates Phase 3 Trial on Breast Cancer Drug (Insider Monkey)
Aug-31-25 12:10AM	Merck & Co. (MRK) Announces First Patient Dosage in HERTHENA-Breast04 Phase 3 Trial (Insider Monkey)
Aug-30-25 10:01PM	How Much Would It Take To Earn $100 A Month From Merck Stock (Benzinga)
02:45AM	Merck Provides New Results for VERQUVO (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction (Business Wire)
Aug-29-25 10:17AM	Is Merck Stock Outperforming the Dow? (Barchart)
10:17AM	ABBV or MRK: Which Stock Should Investors Place Their Bet on in 2025? (Zacks)
Aug-28-25 11:30AM	Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue? (Zacks)
11:13AM	MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate (Zacks)
09:22AM	Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds? (Zacks)
09:21AM	Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line? (Zacks)
06:45AM	Merck to Participate in the 2025 Wells Fargo Healthcare Conference (Business Wire)
05:02AM	Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances (Insider Monkey)
Aug-27-25 07:00AM	HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy (Business Wire)
Aug-26-25 09:35AM	As the Market Rotates, This Healthcare ETF Is Leading the Way (MarketBeat)
09:31AM	Can Label Expansion of Cabometyx Fuel Further Growth for EXEL? (Zacks)
09:17AM	IOVA Stock Drops 6% on $350M Common Stock Offering (Zacks)
Aug-25-25 04:37PM	Dow Loses About 350 Points After Record-Breaking Run (The Wall Street Journal)
04:31PM	Stock Market Today: Dow Drops, Apple Firm Despite Musk Threat; Cathie Wood Loads Up On This Stock (Live Coverage) (Investor's Business Daily)
10:53AM	Stock Market Today: Dow Fall Ahead Of Nvidia Earnings; Dr Pepper Flashes Sell Signals On $18 Billion Deal (Live Coverage) (Investor's Business Daily)
08:45AM	Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now? (Zacks)
06:45AM	Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025 (Business Wire)
Aug-22-25 08:43AM	ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth (Zacks)
Aug-21-25 09:00AM	Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
05:40AM	The biggest Big Pharma losers in the first half of 2025 (Pharma Voice)
Aug-19-25 11:37AM	MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer (Zacks)
09:08AM	Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue? (Zacks)
09:06AM	Can Keytruda Sustain Merck's Growth Through the Rest of 2025? (Zacks)
06:45AM	Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds (Business Wire)
04:53AM	Merck announces EC approval of Ogsiveo for desmoid tumours (Pharmaceutical Technology)
01:00AM	A Tweak to Medicare is Good for Merck. Can It Cure the Troubled Stock? (Barrons.com)
Aug-18-25 05:20PM	Merck's $2 Billion Bet: The Tiny Biotech That Could Save Its Neurology Pipeline (GuruFocus.com)
09:25AM	GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait? (Zacks)
09:23AM	European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors (GlobeNewswire)
08:04AM	Stock Market Today: Dow Jones Futures Fall Ahead Of Big Powell Speech; Amazon, Nvidia Drop (Live Coverage) (Investor's Business Daily)
07:00AM	Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer (Business Wire)
03:58AM	Biopharma layoffs rise as drugmakers tighten belts and reorganize (Pharma Voice)
Aug-17-25 11:41PM	Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration (Insider Monkey)
02:30AM	Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial (Insider Monkey)
Aug-16-25 09:07AM	2 Top Dividend Stocks to Buy on the Dip (Motley Fool)
Aug-15-25 02:30PM	Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness (Insider Monkey)
11:44AM	The Zacks Analyst Blog Highlights Merck, Palo Alto Networks, Freeport-McMoRan and Espey (Zacks)
10:00AM	AstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs (Zacks)
Aug-14-25 11:35PM	Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers (StockStory)
10:01PM	Looking For Yields: Avista, Merck, And Skyworks Solutions Are Consistent Moneymakers (Benzinga)
04:46PM	Top Analyst Reports for Merck, Palo Alto & Freeport (Zacks)
09:11AM	Exelixis Gains 15.6% YTD: How Should You Play the Stock? (Zacks)
Aug-13-25 07:05PM	China pharma firms turn to local reagent suppliers to cut costs and delivery times (Reuters)
06:27PM	3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever (Motley Fool)
12:55PM	PFE New & Acquired Drugs Back 1H Top-Line Growth: Will the Trend Last? (Zacks)
09:33AM	Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB (GlobeNewswire)
08:52AM	Will Zanzalintinib Ease Out EXEL's Reliance on Cabometyx for Growth? (Zacks)
08:41AM	Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge (GlobeNewswire)
07:00AM	Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy (PR Newswire)
06:31AM	Livestock Monitoring Company Evaluation Report 2025 \| Merck & Co., GEA Group, and DeLaval Drive Global Innovations Across Biopharma, Process Technology, and Dairy Farming Automation (GlobeNewswire)
06:05AM	If You're In Your 20's, Consider Buying These 3 Healthcare Stocks (Motley Fool)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams David Michael	EVP,Chief Info&Digital Officer	Aug 04 '25	Option Exercise	79.29	17,119	1,357,366	41,445	Aug 05 08:46 AM
Guindo Chirfi	Chief Marketing Officer	Aug 04 '25	Option Exercise	79.29	36,903	2,926,039	107,409	Aug 05 08:43 AM
Smart Dalton E. III	SVP Fin. - Global Controller	May 03 '25	Option Exercise	83.18	2,050	170,519	10,127	May 05 04:23 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 30 '25	Option Exercise	84.71	464	39,305	8,242	May 02 04:18 PM
Smart Dalton E. III	SVP Fin. - Global Controller	May 02 '25	Option Exercise	83.26	381	31,722	8,464	May 02 04:18 PM
Romanelli Joseph	President, Human Health Int?l	May 02 '25	Option Exercise	83.26	2,262	188,334	24,061	May 02 04:14 PM
Romanelli Joseph	President, Human Health Int?l	Apr 30 '25	Option Exercise	84.71	2,063	174,757	22,816	May 02 04:14 PM
Larson Betty D	EVP, Chief HR Officer	Apr 30 '25	Option Exercise	84.71	11,350	961,458	11,350	May 02 04:12 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Option Exercise	58.08	5,000	290,400	12,040	Apr 29 04:04 PM
Smart Dalton E. III	SVP Fin. - Global Controller	Apr 25 '25	Sale	82.76	4,262	352,723	7,778	Apr 29 04:04 PM
DALTON SMART	Officer	Apr 25 '25	Proposed Sale	82.76	4,262	352,723		Apr 25 04:05 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 19 '25	Sale	84.09	8,500	714,745	30,705	Feb 20 04:01 PM
JOHANNES JACOBUS OOSTHUIZEN	Officer	Feb 19 '25	Proposed Sale	84.09	8,500	714,745		Feb 19 05:09 PM
DAVID WILLIAMS	Officer	Feb 13 '25	Proposed Sale	85.34	6,000	512,057		Feb 13 04:10 PM
Williams David Michael	EVP,Chief Info&Digital Officer	Feb 13 '25	Sale	85.34	6,000	512,057	24,123	Feb 13 04:01 PM
Oosthuizen Johannes Jacobus	President, U.S. Market	Feb 08 '25	Option Exercise	87.28	13,002	1,134,815	45,609	Feb 11 02:59 PM
THULIN INGE G	Director	Feb 06 '25	Buy	88.25	2,833	250,000	2,933	Feb 07 04:09 PM
Downing Cristal N	Chief Comm. & Public Afrs Ofcr	Feb 06 '25	Sale	88.76	2,361	209,551	7,085	Feb 07 04:07 PM
BAKER DOUGLAS M JR	Director	Feb 05 '25	Buy	88.50	15,000	1,327,500	16,000	Feb 07 04:04 PM
CRISTAL DOWNING	Officer	Feb 06 '25	Proposed Sale	88.76	2,361	209,551		Feb 06 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRK

Merck & Co Inc

Upgrade your FINVIZ experience